Revagenix, Inc.
Revagenix is dedicated to delivering urgently needed anti-infective medicines to patients worldwide. Their mission is to create life-changing antibiotics by assembling a highly driven, versatile team with deep insights into the space, applying first-principles to drug design, and ultimately delivering highly differentiated agents that address critical unmet medical needs. They focus on advancing a proprietary pipeline of highly differentiated antibiotic programs in late preclinical stage, each with game-changing potential, and engage in dialogue with stakeholders to build a sustainable antibiotic pipeline and ecosystem.
Industries
Nr. of Employees
small (1-50)
Revagenix, Inc.
Products
Broad-spectrum antibacterial candidate (late preclinical)
A broad-spectrum antibacterial agent developed via a platform chemistry approach, currently in late preclinical development and designed to address a range of infections including complicated urinary tract infection (cUTI), hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), and neonatal sepsis / bloodstream infection.
Antibacterial candidate for chronic pulmonary infections
A development-stage agent designed to reduce the burden of care in treatment of chronic pulmonary infections.
Novel-mechanism agent targeting Gram-negative infections
A preclinical program focused on a novel mechanism of action intended to combat challenging Gram-negative bacterial infections.
Parked Gram-negative antibacterial portfolio (assets available for activation)
Additional Gram-negative antibacterial programs acquired previously and currently held in reserve; estimated ~12–18 months to candidate if reactivated to respond to changing external conditions.
Broad-spectrum antibacterial candidate (late preclinical)
A broad-spectrum antibacterial agent developed via a platform chemistry approach, currently in late preclinical development and designed to address a range of infections including complicated urinary tract infection (cUTI), hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), and neonatal sepsis / bloodstream infection.
Antibacterial candidate for chronic pulmonary infections
A development-stage agent designed to reduce the burden of care in treatment of chronic pulmonary infections.
Novel-mechanism agent targeting Gram-negative infections
A preclinical program focused on a novel mechanism of action intended to combat challenging Gram-negative bacterial infections.
Parked Gram-negative antibacterial portfolio (assets available for activation)
Additional Gram-negative antibacterial programs acquired previously and currently held in reserve; estimated ~12–18 months to candidate if reactivated to respond to changing external conditions.
Services
Federally contracted therapeutic development
Execution of research and development activities under federal contracts and grants to advance anti-infective programs toward the clinic.
CMC and manufacturing strategy services
Drug substance and product development, process development, scale-up strategy, packaging/labeling and logistics services to support clinical supply and commercialization planning.
Clinical development program management
Design and oversight of clinical strategies and execution from IND-enabling activities through registration-enabling studies.
Partnership and alliance development
Formation and management of strategic collaborations with investors, academic institutions, industry partners, and public stakeholders to advance antimicrobial programs.
Federally contracted therapeutic development
Execution of research and development activities under federal contracts and grants to advance anti-infective programs toward the clinic.
CMC and manufacturing strategy services
Drug substance and product development, process development, scale-up strategy, packaging/labeling and logistics services to support clinical supply and commercialization planning.
Clinical development program management
Design and oversight of clinical strategies and execution from IND-enabling activities through registration-enabling studies.
Partnership and alliance development
Formation and management of strategic collaborations with investors, academic institutions, industry partners, and public stakeholders to advance antimicrobial programs.
Expertise Areas
- Antibacterial drug discovery and lead optimization
- Preclinical antibiotic development
- Chemistry, Manufacturing, and Controls (CMC)
- Clinical development and IND/registration programs
Key Technologies
- Medicinal chemistry for novel small molecules
- Platform chemistry for synthesis of complex scaffolds
- In vitro antimicrobial susceptibility and screening assays
- In vivo infection models for efficacy testing